Palvella Therapeutics (NASDAQ:PVLA) Sets New 1-Year High – Here’s What Happened

Palvella Therapeutics, Inc. (NASDAQ:PVLA) shares hit a new 52-week high during trading on Monday . The stock traded as high as $112.00 and last traded at $111.97, with a volume of 61963 shares trading hands. The stock had previously closed at $99.73.

Analyst Ratings Changes

A number of equities research analysts have commented on PVLA shares. BTIG Research raised their price objective on Palvella Therapeutics from $167.00 to $192.00 and gave the company a “buy” rating in a research note on Monday, December 15th. Chardan Capital boosted their price target on shares of Palvella Therapeutics from $110.00 to $174.00 and gave the company a “buy” rating in a research note on Monday, December 15th. Weiss Ratings restated a “sell (d)” rating on shares of Palvella Therapeutics in a report on Monday. Oppenheimer reiterated an “outperform” rating and set a $200.00 price objective on shares of Palvella Therapeutics in a report on Monday, December 15th. Finally, Raymond James Financial reissued a “strong-buy” rating and set a $193.00 target price on shares of Palvella Therapeutics in a research report on Tuesday, December 16th. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $155.60.

Palvella Therapeutics Trading Up 5.5%

The company’s 50-day simple moving average is $87.00 and its 200 day simple moving average is $58.77. The stock has a market cap of $1.25 billion, a P/E ratio of -40.24 and a beta of -0.20.

Palvella Therapeutics (NASDAQ:PVLA) last issued its quarterly earnings results on Monday, November 10th. The company reported ($1.03) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.18). Research analysts anticipate that Palvella Therapeutics, Inc. will post -3.69 earnings per share for the current fiscal year.

Insider Buying and Selling at Palvella Therapeutics

In related news, COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $96.47, for a total value of $415,013.94. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 20.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PVLA. Frazier Life Sciences Management L.P. lifted its position in shares of Palvella Therapeutics by 5.5% during the 1st quarter. Frazier Life Sciences Management L.P. now owns 690,012 shares of the company’s stock valued at $19,313,000 after buying an additional 36,120 shares during the last quarter. AWM Investment Company Inc. purchased a new stake in Palvella Therapeutics during the first quarter valued at about $1,943,000. Millennium Management LLC bought a new position in Palvella Therapeutics during the first quarter worth about $7,553,000. Goldman Sachs Group Inc. purchased a new position in shares of Palvella Therapeutics in the first quarter worth about $533,000. Finally, Woodline Partners LP bought a new stake in shares of Palvella Therapeutics in the first quarter valued at approximately $5,435,000. 40.11% of the stock is currently owned by hedge funds and other institutional investors.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.